| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Prostaglandin E2 receptor EP1 subtype |
|---|
| Ligand | BDBM50165949 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_303059 (CHEMBL828885) |
|---|
| Ki | >3000±n/a nM |
|---|
| Citation |  Hattori, K; Tanaka, A; Fujii, N; Takasugi, H; Tenda, Y; Tomita, M; Nakazato, S; Nakano, K; Kato, Y; Kono, Y; Murai, H; Sakane, K Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. J Med Chem48:3103-6 (2005) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Prostaglandin E2 receptor EP1 subtype |
|---|
| Name: | Prostaglandin E2 receptor EP1 subtype |
|---|
| Synonyms: | PE2R1_HUMAN | PGE receptor, EP1 subtype | PTGER1 | Prostaglandin E2 receptor | Prostaglandin E2 receptor EP1 subtype | Prostaglandin E2 receptor EP1 subtype (EP1) | Prostanoid EP1 receptor |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 41834.57 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P34995 |
|---|
| Residue: | 402 |
|---|
| Sequence: | MSPCGPLNLSLAGEATTCAAPWVPNTSAVPPSGASPALPIFSMTLGAVSNLLALALLAQA
AGRLRRRRSAATFLLFVASLLATDLAGHVIPGALVLRLYTAGRAPAGGACHFLGGCMVFF
GLCPLLLGCGMAVERCVGVTRPLLHAARVSVARARLALAAVAAVALAVALLPLARVGRYE
LQYPGTWCFIGLGPPGGWRQALLAGLFASLGLVALLAALVCNTLSGLALLRARWRRRSRR
PPPASGPDSRRRWGAHGPRSASASSASSIASASTFFGGSRSSGSARRARAHDVEMVGQLV
GIMVVSCICWSPMLVLVALAVGGWSSTSLQRPLFLAVRLASWNQILDPWVYILLRQAVLR
QLLRLLPPRAGAKGGPAGLGLTPSAWEASSLRSSRHSGLSHF
|
|
|
|---|
| BDBM50165949 |
|---|
| n/a |
|---|
| Name | BDBM50165949 |
|---|
| Synonyms: | C-Phenyl-N-{3-[2-((S)-5-phenyl-4-phenyl-oxazol-2-yl)-cyclohex-2-enylmethyl]-benzoyl}-methanesulfonamide | CHEMBL191638 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C36H32N2O4S |
|---|
| Mol. Mass. | 588.715 |
|---|
| SMILES | O=C(NS(=O)(=O)Cc1ccccc1)c1cccc(C[C@@H]2CCCC=C2c2nc(c(o2)-c2ccccc2)-c2ccccc2)c1 |c:24| |
|---|
| Structure | 
|
|---|
Search and Browse
